Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of Qishen Yiqi Dripping Pills in chronic heart failure with preserved ejection fraction
CTR20210996Phase 2Active
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Dec 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of qishen yiqi dripping pills in heart failure with preserved ejection fraction (HFpEF), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Dec 2021; status: active.
02
Drugs
qishen yiqi dripping pills
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on CTR20210996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210996.